$0.80 EPS Expected for Teva Pharmaceutical Industries Limited (TEVA) This Quarter

Brokerages expect that Teva Pharmaceutical Industries Limited (NYSE:TEVA) will announce earnings per share (EPS) of $0.80 for the current quarter, according to Zacks. Five analysts have made estimates for Teva Pharmaceutical Industries’ earnings, with estimates ranging from $0.73 to $1.00. Teva Pharmaceutical Industries reported earnings of $1.38 per share in the same quarter last year, which indicates a negative year over year growth rate of 42%. The firm is scheduled to report its next quarterly earnings report on Monday, February 12th.

According to Zacks, analysts expect that Teva Pharmaceutical Industries will report full year earnings of $3.84 per share for the current year, with EPS estimates ranging from $3.78 to $3.88. For the next fiscal year, analysts expect that the company will post earnings of $2.78 per share, with EPS estimates ranging from $2.34 to $3.02. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Teva Pharmaceutical Industries.

A number of analysts have recently issued reports on TEVA shares. TheStreet cut shares of Teva Pharmaceutical Industries from a “c-” rating to a “d+” rating in a research note on Friday, August 25th. ValuEngine cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Evercore ISI set a $38.00 price objective on shares of Teva Pharmaceutical Industries and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Cantor Fitzgerald set a $17.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Thursday, October 26th. Finally, Credit Suisse Group lowered shares of Teva Pharmaceutical Industries from a “neutral” rating to an “underperform” rating and dropped their target price for the stock from $25.00 to $13.00 in a research report on Wednesday, August 23rd. Seven research analysts have rated the stock with a sell rating, seventeen have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Teva Pharmaceutical Industries has a consensus rating of “Hold” and a consensus target price of $21.65.

Shares of Teva Pharmaceutical Industries (NYSE:TEVA) traded up $1.06 during midday trading on Wednesday, hitting $16.06. 37,014,692 shares of the stock were exchanged, compared to its average volume of 20,490,736. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. The stock has a market capitalization of $15,240.00, a PE ratio of 3.46 and a beta of 0.55. Teva Pharmaceutical Industries has a 1 year low of $10.85 and a 1 year high of $38.31.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be issued a $0.085 dividend. The ex-dividend date of this dividend is Monday, November 27th. This represents a $0.34 annualized dividend and a dividend yield of 2.12%. Teva Pharmaceutical Industries’s dividend payout ratio (DPR) is presently -12.10%.

Institutional investors have recently added to or reduced their stakes in the company. Exane Derivatives bought a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter worth about $571,000. Korea Investment CORP increased its stake in Teva Pharmaceutical Industries by 14.3% in the 3rd quarter. Korea Investment CORP now owns 244,774 shares of the company’s stock worth $4,308,000 after buying an additional 30,674 shares during the period. Financial Counselors Inc. increased its stake in Teva Pharmaceutical Industries by 5.7% in the 2nd quarter. Financial Counselors Inc. now owns 140,599 shares of the company’s stock worth $4,671,000 after buying an additional 7,571 shares during the period. Private Capital Management Inc. increased its stake in Teva Pharmaceutical Industries by 51.3% in the 3rd quarter. Private Capital Management Inc. now owns 26,100 shares of the company’s stock worth $459,000 after buying an additional 8,850 shares during the period. Finally, Lockheed Martin Investment Management Co. purchased a new position in Teva Pharmaceutical Industries in the 3rd quarter worth about $317,000. Hedge funds and other institutional investors own 52.05% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “$0.80 EPS Expected for Teva Pharmaceutical Industries Limited (TEVA) This Quarter” was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://ledgergazette.com/2017/12/09/0-80-eps-expected-for-teva-pharmaceutical-industries-limited-teva-this-quarter.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply